Journal of Neural Transmission

, Volume 120, Supplement 1, pp 55–60

Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards

  • Clemens Warnke
  • Bernd C. Kieseier
  • Hans-Peter Hartung
Neurology and Preclinical Neurological Studies - Review Article

DOI: 10.1007/s00702-013-1055-4

Cite this article as:
Warnke, C., Kieseier, B.C. & Hartung, H. J Neural Transm (2013) 120: 55. doi:10.1007/s00702-013-1055-4

Abstract

Multiple sclerosis (MS), the most common cause of neurological disability in young adults, represents the prototypic inflammatory autoimmune disorder of the central nervous system. Increased understanding of the immunopathological processes underlying this disease, advances in biotechnology, development of powerful magnetic resonance imaging technologies together with improvements in clinical trial design have translated into a variety of new and innovative therapeutic avenues. In this review, we will highlight recent therapeutic developments in MS and critically discuss new challenges associated with these new treatment options.

Keywords

Multiple sclerosisRelapsing remitting MSRiskBenefitTreatment choicesImmunotherapy

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Clemens Warnke
    • 1
  • Bernd C. Kieseier
    • 1
  • Hans-Peter Hartung
    • 1
  1. 1.Department of Neurology, Medical FacultyHeinrich-Heine-University DüsseldorfDuesseldorfGermany